Should pertuzumab be used as part of neoadjuvant treatment prior to the release of the APHINITY trial results?

The 2016 publication entitled “5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial” in Lancet Oncology provided an opportunity to revisit the combination of pertuzumab and trastuzumab as a neoadjuvant treatment for HER2-positive breast cancer (1). Pertuzumab is the first Food and Drug Administration (FDA)-approved drug in the neoadjuvant setting (2).